| 1. |
|
|
| 2. |
|
|
| 3. |
- Eriksson, Mikael, et al.
(författare)
-
MAX4, a 3 GeV light source with a flexible injector
- 2002
-
Ingår i: 8th European Particle Accelerator Conference. ; , s. 686-687
-
Konferensbidrag (refereegranskat)abstract
- The MAX4 ring is intended to be the future user facility at MAXlab. The high-brilliance 3 GeV storage ring, equipped with small gap, short period superconducting undulators, demonstrates a high mean brilliance over a wide photon energy spectrum. The ring itself is defined from the routine operation of the small gap insertion devices, which is reflected in the small aperture of the ring magnets. The development of future light sources, like the free electron laser and energy recovery systems, opens up new challenging possibilities to create high brilliance, short pulse radiation. This development is today far from being mature, a strong development of new ideas and techniques will most probably take place during the next decade(s). The MAX4 full-energy injector is constructed to incorporate these future developments. The proposed 3 GeV energy recovery race-track microtron will open up the possibility of topping up injection and to deliver Fourier transform limited spontaneous as well as coherent radiation up to the hard X-ray spectral region
|
|
| 4. |
- Ermann, Joerg, et al.
(författare)
-
CD4+CD25+ T cells facilitate the induction of T cell anergy
- 2001
-
Ingår i: Journal of Immunology. - Rockville Pike, Bethesda, MD : The American Association of Immunologists, Inc.. - 0022-1767 .- 1550-6606. ; 167:8, s. 4271-4275
-
Tidskriftsartikel (refereegranskat)abstract
- T cell anergy is characterized by the inability of the T cell to produce IL-2 and proliferate. It is reversible by the addition of exogenous IL-2. A similar state of unresponsiveness is observed when the proliferative response of murine CD4+CD25- T cells is suppressed in vitro by coactivated CD4+CD25+ T cells. We have developed a suppression system that uses beads coated with anti-CD3 and anti-CD28 Abs as surrogate APCs to study the interaction of CD4+CD25+ and CD4+CD25- T cells in vitro. CD4+CD25+ T cell-induced suppression, in this model, was not abrogated by blocking the B7-CTLA-4 pathway. When the CD4+CD25- T cells were separated from the CD4+CD25+ suppressor cells after 24 h of coactivation by the Ab-coated beads, the CD4+CD25- T cells were unable to proliferate or to produce IL-2 upon restimulation. The induction of this anergic phenotype in the CD4+CD25- T cells correlated with the up-regulated expression of the gene related to anergy in lymphocytes (GRAIL), a novel anergy-related gene that acts as a negative regulator of IL-2 transcription. This system constitutes a novel mechanism of anergy induction in the presence of costimulation.
|
|
| 5. |
|
|
| 6. |
- Weinreb, Neal J, et al.
(författare)
-
Gaucher disease type 1 : revised recommendations on evaluations and monitoring for adult patients.
- 2004
-
Ingår i: Semin Hematol. - 0037-1963. ; 41:4 Suppl 5, s. 15-22
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- For patients with type 1 Gaucher disease, challenges to patient care posed by clinical heterogeneity, variable progression rates, and potential permanent disability that can result from untreated or suboptimally treated hematologic, skeletal, and visceral organ involvement dictate a need for comprehensive, serial monitoring. An updated consensus on minimum recommendations for effective monitoring of all adult patients with type 1 Gaucher disease has been developed by the International Collaborative Gaucher Group (ICGG) Registry coordinators. These recommendations provide a schedule for comprehensive and reproducible evaluation and monitoring of all clinically relevant aspects of this disease. The initial assessment should include confirmation of deficiency of beta-glucocerebrosidase, genotyping, and a complete family medical history. Other assessments to be performed initially and at regular intervals include a complete physical examination, patient-reported quality of life using the SF-36 survey, and assessment of hematologic (hemoglobin and platelet count), visceral, and skeletal involvement, and biomarkers. Specific radiologic imaging techniques are recommended for evaluating visceral and skeletal pathology. All patients should undergo comprehensive regular assessment, the frequency of which depends on treatment status and whether therapeutic goals have been achieved. Additionally, reassessment should be performed whenever enzyme therapy dose is altered, or in case of significant clinical complication.
|
|
